Markets
← Back to Sector Map
DXCM
Health Care · Health Care EquipmentDEXCOM INC
$68.38
+1.89%
AI Research
Type 2 diabetes CGM data presented → Breakthrough outcomes at ATTD 2026 conference
PositiveBuyPT $85.50
DexCom unveiled Type 2 diabetes CGM data at ATTD 2026 showing breakthrough outcomes with Dexcom G7 linked to A1C and weight management improvements, plus fewer DKA hospital visits in non-insulin patients. Citigroup raised PT from $77 to $84 with Buy rating on March 11, while consensus rating is Moderate Buy with $85.50 PT consensus. Stock faces 3.49% weekly decline and 8.3% 30-day drop, though 19 analysts maintain Buy or Strong Buy ratings with strong institutional interest.
Key Stats
Market Cap$25.9B
P/E (TTM)31.7
Fwd P/E22.2
Beta1.53
Div Yield—
Prev Close$67.11
52-Week Range
$54.11$68.38$89.98